Two new clinical papers provide evidence for on-demand and prophylactic use of potential HAE treatment, deucrictibant
A potential HAE treatment, called deucrictibant, could be used as an on-demand and prophylactic treatment, according to two new publications in the journal Lancet Haematology. A summary of these clinical trial publications is:
- CHAPTER-1, a study of deucrictibant for the prophylactic treatment of HAE attacks, demonstrated a statistically significant reduction in the occurrence of attacks and clinically meaningful improvements in disease control and health-related quality of life.
- RAPIDe-1, a study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, demonstrated a statistically significant reduction in severity of attacks, as well as a reduced time to symptom relief and resolution.
- In both studies, deucrictibant was well tolerated at all doses tested.
Marc A. Riedl, MD, MS, Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center at the University of California San Diego (UCSD), and investigator in both studies, commented: “Since HAE is a bradykinin-mediated disease, regulation of bradykinin signaling through B2 receptor antagonism could both prevent HAE attacks and manage angioedema symptoms when they occur. Based on these results, deucrictibant is emerging as a potentially unique oral therapy for HAE, providing on-demand and preventative treatment.”
Peng Lu MD PhD, Chief Medical Officer of Pharvaris, said: “Icatibant use has established bradykinin B2 receptor antagonism as the standard-of-care approach for on-demand treatment of HAE attacks. The RAPIDe-1 data are the first-ever clinical study data supporting deucrictibant as an oral on-demand therapy, and the CHAPTER-1 data are the first-ever clinical study data supporting bradykinin B2 receptor antagonism as an effective approach for prophylaxis of HAE attacks.”
(Source: Pharvaris)